Literature DB >> 17428640

Infective endocarditis caused by USA300 methicillin-resistant Staphylococcus aureus (MRSA).

N Z Haque1, S L Davis, C L Manierski, D Vager, S M Donabedian, M B Perri, R Sabbagh, F Cheema, M J Zervos.   

Abstract

We report seven cases of infective endocarditis caused by USA300 methicillin-resistant Staphylococcus aureus (MRSA) at an urban, tertiary care, academic institution. Five strains were community associated and two were healthcare associated. All patients were injection drug users. Staphylococcus aureus isolates were characterised as USA300-type MRSA using pulsed-field gel electrophoresis. Five cases were right-sided endocarditis and two cases were left-sided. The mean length of in-hospital antimicrobial therapy was 23 days and the mean length of total antibiotic therapy was 55 days. Complications included heart failure resulting in valve replacement in one patient as well as death in that patient. As USA300 strains of MRSA continue to increase in prevalence, clinicians must be aware of the increasing spectrum of illness in considering management and prevention strategies.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17428640     DOI: 10.1016/j.ijantimicag.2007.02.007

Source DB:  PubMed          Journal:  Int J Antimicrob Agents        ISSN: 0924-8579            Impact factor:   5.283


  13 in total

Review 1.  Virulence strategies of the dominant USA300 lineage of community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA).

Authors:  Lance R Thurlow; Gauri S Joshi; Anthony R Richardson
Journal:  FEMS Immunol Med Microbiol       Date:  2012-03-05

2.  msaABCR operon positively regulates biofilm development by repressing proteases and autolysis in Staphylococcus aureus.

Authors:  Gyan S Sahukhal; Justin L Batte; Mohamed O Elasri
Journal:  FEMS Microbiol Lett       Date:  2015-01-18       Impact factor: 2.742

Review 3.  Community-associated methicillin-resistant Staphylococcus aureus: epidemiology and clinical consequences of an emerging epidemic.

Authors:  Michael Z David; Robert S Daum
Journal:  Clin Microbiol Rev       Date:  2010-07       Impact factor: 26.132

4.  How Staphylococcus aureus biofilms develop their characteristic structure.

Authors:  Saravanan Periasamy; Hwang-Soo Joo; Anthony C Duong; Thanh-Huy L Bach; Vee Y Tan; Som S Chatterjee; Gordon Y C Cheung; Michael Otto
Journal:  Proc Natl Acad Sci U S A       Date:  2012-01-09       Impact factor: 11.205

5.  Rot is a key regulator of Staphylococcus aureus biofilm formation.

Authors:  Joe M Mootz; Meredith A Benson; Cortney E Heim; Heidi A Crosby; Jeffrey S Kavanaugh; Paul M Dunman; Tammy Kielian; Victor J Torres; Alexander R Horswill
Journal:  Mol Microbiol       Date:  2015-02-26       Impact factor: 3.501

6.  Interconnections between Sigma B, agr, and proteolytic activity in Staphylococcus aureus biofilm maturation.

Authors:  Katherine J Lauderdale; Blaise R Boles; Ambrose L Cheung; Alexander R Horswill
Journal:  Infect Immun       Date:  2009-02-02       Impact factor: 3.441

Review 7.  Community-associated meticillin-resistant Staphylococcus aureus infections: epidemiology, recognition and management.

Authors:  Mukesh Patel
Journal:  Drugs       Date:  2009       Impact factor: 9.546

8.  Molecular epidemiology of methicillin-resistant Staphylococcus aureus bloodstream isolates in urban Detroit.

Authors:  Thea Chua; Carol L Moore; Mary B Perri; Susan M Donabedian; William Masch; Dora Vager; Susan L Davis; Kaitlin Lulek; Benjamin Zimnicki; Marcus J Zervos
Journal:  J Clin Microbiol       Date:  2008-05-28       Impact factor: 5.948

9.  Infective endocarditis on mitral annular calcification: a case report.

Authors:  Giovanni Minardi; Paolo G Pino; Martina Sordi; Herribert Pavaci; Carla Manzara; Giovanni Pulignano; Enrico Natale; Carlo Gaudio
Journal:  Cases J       Date:  2009-11-20

10.  Nuclease modulates biofilm formation in community-associated methicillin-resistant Staphylococcus aureus.

Authors:  Megan R Kiedrowski; Jeffrey S Kavanaugh; Cheryl L Malone; Joe M Mootz; Jovanka M Voyich; Mark S Smeltzer; Kenneth W Bayles; Alexander R Horswill
Journal:  PLoS One       Date:  2011-11-11       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.